Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.
|
31685258 |
2020 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma.
|
31171645 |
2020 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
|
30862686 |
2019 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated a next-generation phosphoinositide-3-kinase-δ inhibitor (PI3K-δi), umbralisib, plus a Bruton tyrosine kinase inhibitor (BTKi), ibrutinib, in relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma.
|
30558987 |
2019 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib is a small molecule drug that targets Bruton's tyrosine kinase in B-cell malignancies and is highly efficient at killing mantle cell lymphoma and chronic lymphocytic leukemia.
|
30663221 |
2019 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
|
30940906 |
2019 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Newer and more selective BTK inhibitors are currently in clinical development, including acalabrutinib, which is currently US FDA approved for previously treated mantle cell lymphoma.
|
30927175 |
2019 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
|
30413649 |
2019 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
USFDA has approved a novel Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (ACA) for the treatment of mantle cell lymphoma in adults.
|
30453157 |
2019 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, 12a showed higher selectivity against BTK and exhibited robust antiproliferative effects in both mantle cell lymphoma cell lines and primary patient tumor cells.
|
31031018 |
2019 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma.
|
29590547 |
2018 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma.
|
29241979 |
2018 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
|
29912596 |
2018 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
|
28905990 |
2018 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
|
30052472 |
2018 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
|
29392403 |
2018 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, a Bruton's tyrosine kinase inhibitor, is the newest drug in the arsenal that has shown promising efficacy in relapsed mantle cell lymphoma.
|
26970573 |
2017 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma.
|
26961147 |
2016 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Targeting the HDACs by using either RNA interference against HDAC1 in CLL or a small molecule inhibitor (HDACi) in CLL and mantle cell lymphoma restored the expression of the BTK-targeting miRs with loss of BTK protein and downstream signaling and consequent cell death.
|
27756747 |
2016 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.
|
27157620 |
2016 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has produced remarkable clinical response in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma.
|
25189416 |
2015 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
|
25797245 |
2015 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib (PCI-32765) is the most advanced BTK inhibitor in clinical testing, with ongoing phase III clinical trials in patients with chronic lymphocytic leukemia and mantle-cell lymphoma.
|
24778403 |
2014 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
|
25082755 |
2014 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
|
23962569 |
2013 |